ABSTRACT -Excessive production of transforming growth factor-β1 (TGFβ1) plays an important role in lung fibrosis, in which the differentiation of fibroblasts into myofibroblasts is a key process. Increased formation of reactive oxygen species (ROS) induced by TGFβ1 is a common pathological feature of fibrosis. In the present study, probucol and lovastatin, which are therapeutics used for hyperlipidemia and proposed to act as anti-oxidants, were examined in terms of their effect on TGFβ1-induced formation of ROS and expression of α-smooth muscle actin (αSMA), a myofibroblast marker, in human fetal lung fibroblasts (HFL1 cells). The effects of anti-oxidative enzymes and reagents including N-acetyl-L-cysteine, α-tocopherol, and lecithinized-superoxide dismutase (SOD) on TGFβ1-induced expression of αSMA were also examined. Treatment with probucol (30 μM) and lovastatin (1 μM and 3 μM), in addition to lecithinized-SOD, significantly inhibited the TGFβ1-induced formation of ROS and αSMA. Other anti-oxidants including N-acetyl-L-cysteine had marginal effects on αSMA expression under the conditions. Probucol and lovastatin, established therapeutics, may be worth trying in patients with both lung fibrosis and hypercholesterolemia.
INTRODUCTION
Transforming growth factor-β1 (TGFβ1) regulates a wide variety of cellular functions in normal development and tissue homeostasis, and is involved in pathogenesis. It is reported that dys-regulated expression of TGFβ1 plays an important role in the pathogenesis of aberrant airway development in a number of chronic lung diseases including idiopathic pulmonary fibrosis (IPF, Hu et al., 2003; Gauldie et al., 2006; Liu and Gaston Pravia, 2010) . The appearance of fibroblast foci is one pathological hallmark of IPF, and a greater profusion of fibroblast foci is associated with a worse prognosis (King et al., 2001; Hu et al., 2003; Gauldie et al., 2006) . Myofibroblasts, showing a phenotype intermediate between that of fibroblasts and smooth muscle cells, are the key effector for fibrogenesis and characterized by the expression of α-smooth muscle actin (αSMA). In addition, treatment of patients with drugs such as methotrexate and bleomycin has been known to cause pulmonary fibrotic responses including expression of αSMA (Keane et al., 2005; Ohbayashi et al., 2010) TGFβ1 is a potent fibrogenic cytokine and mediates the conversion of dermal fibroblasts into myofibroblasts. Since TGFβ1-mediated fibrosis is regulated by oxidative stress and/or cellular redox state (Kinnula and Crapo, 2003; Kinnula et al., 2005; Liu and Gaston Pravia, 2010) , redox modulatory therapy may be useful for treatment. Anti-oxidants such as GSH and N-acetyl-L-cysteine (NAC) have been tried clinically for the treatment of lung fi brotic diseases, but the effi cacy of these reagents remains to be comprehensively evaluated (Kinnula et al., 2005; Liu and Gaston Pravia, 2010) . In the present study, we examined the effects of probucol and lovastatin, which are lipid-lowering agents with anti-oxidative properties, on TGFβ1-induced expression of αSMA in human fetal lung fibroblasts (HFL1 cells). Also, we examined the effects of anti-oxidative enzymes including lecithinized-superoxide dismutase (SOD) and anti-oxidants such as NAC and glutathione ethyl ester on TGFβ1-induced expression of αSMA under same conditions. Anti-oxidant activities of probucol and lovastatin were examined by measuring the level of intracellular reactive oxygen species (ROS) in HFL1 cells.
MATERIALS AND METHODS

Cell culture
HFL1 cells (lung, diploid, human, passage 14) were purchased from American Type Culture Collection (Lot No. 4619685, Manassas, VA, USA). The HFL1 cells (1 x 10 5 /well) were cultured in DMEM supplemented with 5% fetal bovine serum (Hyclone Co., Logan, UT, USA). The cells at 60~70% confl uence were incubated with serum-free medium containing 0.1% albumin for 24 hr, and then stimulated for 48 hr with 10 ng/ml TGFβ1 in 5% serum-containing medium. Addition of the anti-oxidative enzymes and reagents (20 μl solution) was repeated twice in the cells in the same plate (5 ml of medium): the fi rst (20 μl) and second (20 μl) treatments were carried out 2 hr before and 24 hr after the TGFβ1 treatment, respectively, and the total concentration achieved by the two applications is shown. Cytotoxicity was determined by counting cell number or by leakage of lactate dehydrogenase (Kurosawa et al., 2009) .
Reagents
Human TGFβ1 was purchased from PeproTech (#100-21C, Rocky Hill, CT, USA). Lovastatin and probucol were from Cayman (Ann Arbor, MI, USA) and Otsuka (Tokushima, Japan), respectively, and formula of the two reagents were shown in Fig. 1 . Catalase (#3556, from human erythrocytes), SOD from E. coli (S5639, Mn-SOD), SOD from bovine brain erythrocytes (#S2515, CuZn-SOD), NAC, (±)-α-tocopherol, and glutathione ethyl ester were from Sigma (St. Louis, MO, USA). Lecithinized-SOD (phosphatidylcholine (PC)-bound with human CuZn-SOD, 3,000 U/mg) was a gift from LTT BioPharm (Tokyo, Japan). The concentrations of reagents and enzymes used in this study were the same as those in previous studies using cultured cells: lovastatin (Watts et al., 2006; Ghavami et al., 2010) , probucol (Tsukamoto et al., 2000; Du et al., 2010) , anti-oxidative enzymes including catalase and SOD (Tsukamoto et al., 2000; Qi et al., 2009) , lecithinized-SOD (Igarashi et al., 1994) , and antioxidants such as NAC and glutathione ethyl ester (Sugiura et al., 2009; Ono et al., 2009; Felton et al., 2009 ).
Immunoblotting of αSMA
Treated cells were harvested and homogenized in cell lysis buffer as described with minor modifications (Orido et al., 2010) . Bands immunoreactive to anti-αSMA antibody (Clone 1A4, Sigma) and anti-β-tubulin antibody (TUB2.1, Sigma) were visualized using a chemiluminescent reagent (Amersham, Buckinghamshire, UK). The effects of reagents were evaluated against the net increase of TGFβ1-induced expression of αSMA
Measurement of intracellular ROS
The level of intracellular ROS was measured as a function of 2',7'-dichloro-fl uorescein (DCF) fl uorescence as described previously (Kurosawa et al., 2009 ) with minor modifications. Briefly, TGFβ1-treated HFL1 cells were incubated with 5 μM non-fluorescent 2',7'-dichlorodihydro-fluorescein diacetate (DCFH-DA, Sigma) in the dark, and DCF fl uorescence was observed under a laserscanning confocal microscope (Carl Zeiss, Oberkochen, Germany: 488 nm excitation and evoked emission fi ltered with a 520-nm fi lter). DCFH is sensitive to oxidation by peroxynitrite, H 2 O 2 , and hydroxyl radical, while it is not Fig. 1 . Formula of probucol and lovastatin. Vol. 36 No. 6 suitable for the measurement of nitric oxide and superoxide anion in biological systems (Myhre et al., 2003) . The images were obtained in a fl uorescent detector with the indicated PMT voltages. The images with greater PMT voltages showed a lower level of intracellular ROS. An increase in ROS is shown as a pseudo-color in Fig. 4 .
Data presentation
Data are the mean ± S.D. for the indicated number of independent experiments. The statistical signifi cance of differences between two groups was assessed using the two-tailed Student's t-test. Multiple comparisons against a single control group were made by a one-way analysis of variance followed by Tukey's test. P < 0.05 was considered signifi cant.
RESULTS
Effects of anti-oxidative enzymes on TGFβ1-induced expression of αSMA
Stimulation of HFL1 cells with 10 ng/ml TGFβ1 signifi cantly enhanced αSMA expression at 48 hr: the value was 224 ± 35% (n = 7, P < 0.05) compared with the control without TGFβ1 ( Fig. 2A) . The response was marginal at 24 hr. Next, we examined the effects of anti-oxidative enzymes and reagents on the response to TGFβ1. In preliminary experiments, a single application of the test compounds such as lecithinized-SOD and probucol did not have a signifi cant effect on the TGFβ1-induced response. Thus, taking account of the possible degradation and/or time-dependent invalidity of the tested compounds, the application was repeated twice at an interval of 24 hr in the subsequent experiments. Treatment with 100 μg/ml (300 U/ml) and 500 μg/ml (1,500 U/ml) lecithinized-SOD ( Fig. 2A) and 1,000 U/ml catalase (Fig. 2B ) reduced the expression of αSMA induced by TGFβ1. The decrease caused by these anti-oxidative enzymes was slight (approximately 20~30% inhibition), but signifi cant (Fig. 2C) . In two preliminary experiments, treatment with both lecithinized-SOD and catalase (500 μg/ml and 1,000 U/ml, respectively) additionally inhibited the TGFβ1-evoked response: the values were 45% and 52% of the control (100%) without the enzymes. The effects of 500 μg/ml lecithinized-SOD and 1,000 U/ml catalase on αSMA expression without TGFβ1 were variable: 74.6 ± 25.8 (% of control, n = 5) and 84.2 ± 12.4% (n = 5), respectively. Although treatment with lecithinized-SOD solution produced small white particles, probably lecithin vesicles, in the medium after approximately 10 hr, the reagent did not show cytotoxicity, and lecithin vesicles without SOD showed neither an inhibitory effect on αSMA level nor cytotoxicity (data not shown). The effects of other anti-oxidative enzymes, CuZn-SOD and Mn-SOD, at 300 μg/ml on αSMA expression with TGFβ1 were marginal: the values were 72.6 ± 28.1% and 84.8 ± 17.3%, respectively (n = 3). Also, the enzymes had no Fig. 2 . Effects of anti-oxidative enzymes on expression of αSMA in HFL1 cells. HFL1 cells were pretreated with 50 μg/ml and 250 μg/ml of lecithinized-SOD (PC-SOD, Panel A) and catalase (500 U/ml, Panel B) for 2 hr, and then stimulated with 10 ng/ml of TGFβ1 in medium containing 5% serum. These same concentrations of enzymes were repeatedly added to the same dishes 24 hr after TGFβ1 treatment, and αSMA levels were determined 48 hr after the stimulation. Total concentrations of the enzymes following two applications are shown. Levels of αSMA and β-tubulin are shown in the upper and lower panels, respectively. Pictures are from typical representative experiments, and quantitative data are shown in Panel C. The data were calculated as the ratio of αSMA to β-tubulin and normalized as a percentage of the TGFβ1-induced response. Data are the mean ± S.D. for the indicated number of independent experiments. a P < 0.05, signifi cantly different from the control.
effect on αSMA expression without TGFβ1: approximately 90 ± 15% (n = 4).
Effects of anti-oxidative reagents on TGFβ1-induced expression of αSMA Under our conditions, treatment with 3 mM NAC had variable effects on the TGFβ1-induced expression of αSMA after 48 hr: half inhibition in two experiments and no inhibition in the other three. Treatment with 6 mM glutathione ethyl ester did not inhibit the TGFβ1-evoked response: the value was 97.4 ± 6.5% (n = 3), the same as the control value without the anti-oxidant. The level of αSMA without TGFβ1 was not modified by these anti-oxidants. Treatment with 60 μM α-tocopherol did not affect αSMA expression: the value without TGFβ1 was 102 ± 6% (% of control, n = 4) and the TGFβ1-induced response was 94.6 ± 11.3% (n = 5) in the presence of α-tocopherol.
Next, we investigated the effects of probucol and lovastatin, which are used clinically and proposed to have an anti-oxidative effect (Liao and Laufs, 2005; Alexeeff et al., 2007; Yamashita and Matsuzawa, 2009 ), on αSMA expression. Treatment with 10 μM and 30 μM probucol signifi cantly inhibited the TGFβ1-induced expression of αSMA (Fig. 3) . Probucol did not modify the expression of αSMA without TGFβ1. Treatment with 1 μM and 3 μM lovastatin signifi cantly inhibited the TGFβ1-induced expression of αSMA. In the absence of TGFβ1, treatment with 1 μM lovastatin significantly decreased the basal level of αSMA (71.3 ± 5.8%, n = 3, P < 0.05), although 3 μM lovastatin had no effect. Treatment with statins for 48 hr is reported to cause cell death in human lung mesenchymal cells (Ghavami et al., 2010) , but lovastatin at the concentrations tested was not cytotoxic (data not shown).
Effects of probucol, lovastatin, and lecithinized-SOD on the TGFβ1-induced increase in ROS
First, we confirmed that the treatment with 5 μM H 2 O 2 for 90 min increased ROS levels in HFL1 cells (Fig. 4A) . Treatment with 10 ng/ml TGFβ1 for 16 hr increased ROS levels (Fig. 4B) , and the response was approximately 8-fold of that in the control cells (Fig. 5) . The TGFβ1-induced response was marginal at 2 hr and 4 hr, but marked from 6 hr after stimulation (data not shown). Treatment of HFL1 cells with 500 μg/ml lecithinized-SOD, 30 μM probucol, and 3 μM lovastatin significantly inhibited the TGFβ1-induced increase of ROS levels 16 hr after the stimulation (Figs. 4B and 5) . The reagents including lecithinized-SOD did not change the basal ROS levels in control cells without TGFβ1 (data not shown). The treatment with the reagents including probucol and lovastatin showed partial and/or limited inhibitory effects on the H 2 O 2 -induced response probably because of a large amount of ROS in H 2 O 2 -treated cells (PMT voltage, 380 in a detector).
DISCUSSION
Inhibition of TGFβ1-induced expression of αSMA by probucol and lovastatin
Oxidative stress has been shown to regulate fibrosis, specifically TGFβ1-induced fibrosis, in various cells including lung fi broblasts and lung epithelial cells (Sugiura et al., 2009; Felton et al., 2009; Liu and Gaston Pravia, 2010) . Oxidative stress (i.e. ROS) includes superoxide radicals, hydrogen peroxide (H 2 O 2 ), and hydroxyl radicals. Since DCFH is sensitive to H 2 O 2 and hydroxyl radical, but not superoxide radicals, in biological systems (Myhre et al., 2003) , TGFβ1 appeared to increase H 2 O 2 and hydroxyl radical as ROS in HFL1 cells under our conditions. Probucol is a diphenolic compound with anti-oxidant activity that reduces arteriosclerosis and restenosis in coronary arteries (Yamashita and Matsuzawa, 2009) . In this study, treatment with probucol inhibited the TGFβ1-induced formation of ROS at 16 hr ( Fig. 4B ) and expression of αSMA at 48 hr (Fig. 3) after TGFβ1 stimulation. Statins including lovastatin are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, and also block the isoprenylation and resulting activation of small GTP-binding proteins such as the Rho family. Statins attenuate oxidative stress in cells through inhibition of Rac1, a member of the Rho family, and regulation of ROS formation by NADPH oxidase (Liao and Fig. 4 . Effects of lecithinized-SOD, probucol, and lovastatin on ROS levels. In Panel A, HFL1 cells were stimulated with vehicle (None) or 5 μM H 2 O 2 for 90 min. In Panel B, the cells were pre-treated with 500 μg/ml lecithinized-SOD (PC-SOD), 30 μM probucol, and 3 μM lovastatin for 2 hr, and then stimulated with 10 ng/ml TGFβ1 for 16 hr. Then, the cells underwent a DCF fl uorescence assay for the determination of ROS levels. The images were obtained at an enhanced intensity in a fl uorescent detector with the indicated PMT voltages. The images obtained with greater PMT voltages showed a lower level of intracellular ROS. An increase in ROS is shown as a pseudo-color, and two pictures are from two different fi elds in the same dish. Quantitative data are shown in Fig. 5 . Laufs, 2005) . Treatment with lovastatin at 3 μM inhibited the TGFβ1-induced formation of ROS and expression of αSMA. We showed for the fi rst time that probucol and lovastatin, which are established compounds in clinical use with good safety profi les, inhibited the TGFβ1-induced formation of ROS and resulting expression of αSMA in HFL1 cells. Oxidative stress can induce TGFβ gene expression, and a synthesized latent form of TGFβ should be activated by ROS for binding to its receptors (Gauldie et al., 2006; Liu and Gaston Pravia, 2010) . It was found that lung fi broblasts expressed higher levels of TGFβ1 and TGFβ2 mRNA in response to exogenous TGFβ1, suggesting a positive autocrine feedback mechanism (DiCamillo et al., 2006; Blaauboer et al., 2011) . Treatment of mice with lovastatin (p.o., 10 mg/kg) attenuated subchronic radiation effects including increased expression of TGFβ in lung cells (Ostrau et al., 2009) . Thus, reagents having anti-oxidative activity may inhibit the TGFβ1-induced expression of αSMA via multiple mechanisms. In the present study, lovastatin at 1 μM had a greater inhibitory effect on the TGFβ1-induced expression of αSMA than did 30 μM probucol. Probucol is proposed to scavenge ROS by the two phenol moieties of the reagent (Yamashita and Matsuzawa, 2009) , and lovastatin appears to inhibit formation of ROS by enzymatic inhibition. This character of lovastatin may explain its greater inhibition of αSMA expression. On the basis of fi ndings that the concentration of GSH is decreased in the lung-lining fl uid of patients with fi brotic disease, GSH and NAC have been used clinically for the treatment of various lung fi brotic diseases, although the effi cacy of these reagents remains to be comprehensively evaluated (Kinnula et al., 2005; Sadowska et al., 2006; Liu and Gaston Pravia, 2010) . It is reported that glutathione redox status regulated TGFβ1-induced fi brogenic effects including expression of αSMA in lung cells including HFL1 cells (Sugiura et al., 2009; Ono et al., 2009; Felton et al., 2009) . Under our conditions, however, treatment with neither NAC nor glutathione ethyl ester affected αSMA levels. This discrepancy may be explained by the following factors. Oxidative/redox conditions including GSH metabolism and ROS formation are dependent on various cellular conditions including cell clones, passages, and serum. In fact, the expression and/or endogenous level of αSMA in HFL1 cells differs among reports: a substantial level was found in both this study and previous reports (Ichikawa et al., 2008; Ono et al., 2009) , but a trace amount of the protein was reported elsewhere (Sugiura et al., 2009) . Felton et al. (2009) reported that repeated application of 5 mM NAC (5 times, at every 24 hr for 5 days) decreased TGFβ1-induced expression of αSMA in alveolar epithelial cells, and the single application had no effect. Thus, application of the anti-oxidants at tested concentrations (2 times) in the present study may be not enough to regulate glutathione redox status in HFL1 cells, and additional experiments on the application of NAC (dose and time) are in progress in our laboratory. Also, multiple pools and/or sub-cellular compartments of ROS, which differed in sensitivity to water-soluble antioxidants and to lipid-soluble anti-oxidants, are proposed (Moldovan and Moldovan, 2004) . The effects of lipid soluble anti-oxidants and statins on TGFβ1-induced αSMA expression should be solved.
Inhibition of αSMA expression by lecithinized-SOD
SODs are the only enzymatic system decomposing superoxide radicals to H 2 O 2 and are hypothesized to play a signifi cant role against oxidative stress, specifi cally in lung (Kinnula et al., 2005; Gao et al., 2008) . Treatrment with lecithinized-SOD (also shown as PC-SOD) significantly inhibited TGFβ1-induced expression of αSMA (Fig. 2) . Although addition of lecithinized-SOD can increase H 2 O 2 formation from superoxide radicals in TGFβ1-stimulated cells, endogenous catalase may effec- tively reduce H 2 O 2 level in cells. Liposome encapsulation of anti-oxidative enzymes is postulated to provide a longer half-life and better penetration of target cells (Igarashi et al., 1994; Kinnula and Crapo, 2003) . Lecithinized-SOD appeared to have characteristics similar to liposome-encapsulated SOD, and treatment with the reagent protected against pulmonary fibrosis in mice (Tamagawa et al., 2000; Tanaka et al., 2010) and in a patient with amyopathic dermatomyositis . Although particles probably due to lecithin formed in the culture medium, they were not cytotoxic. The usefulness of lecithinized-SOD should be examined in animal models and patients with lung fibrotic diseases. In summary, the present study demonstrated that probucol and lovastatin, which are established compounds in clinical use with safety profiles, inhibited the TGFβ1-induced formation of ROS and resulting expression of αSMA in HFL1 cells. Lecithinized-SOD also decreased the TGFβ1-induced expression of αSMA. Recent studies show probucol and statins acting as anti-oxidants to be useful for the prevention and/or treatment of various diseases including declines in lung function (Franks and Gardner, 2006; Watts et al., 2006; Alexeeff et al., 2007; Tanous et al., 2008; Yamashita and Matsuzawa, 2009 ). Probucol and lovastatin may be worth testing as therapeutic agents for patients with both lung fibrosis and hypercholesterolemia.
